Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.04 USD | -0.78% | -2.30% | -6.40% |
Financials (USD)
Sales 2024 * | 99.02M | Sales 2025 * | 181M | Capitalization | 479M |
---|---|---|---|---|---|
Net income 2024 * | -126M | Net income 2025 * | -62M | EV / Sales 2024 * | 4.28 x |
Net cash position 2024 * | 55.62M | Net cash position 2025 * | 277M | EV / Sales 2025 * | 1.11 x |
P/E ratio 2024 * |
-3.91
x | P/E ratio 2025 * |
-8.41
x | Employees | 200 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.65% |
Latest transcript on UroGen Pharma Ltd.
1 day | -0.78% | ||
1 week | -2.30% | ||
Current month | -6.40% | ||
1 month | -6.40% | ||
3 months | -12.90% | ||
6 months | +26.94% | ||
Current year | -6.40% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 19-01-02 | |
Dong Kim
DFI | Director of Finance/CFO | 47 | 21-07-31 |
Jason Smith
CMP | Compliance Officer | 52 | 20-09-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arie Belldegrun
CHM | Chairman | 74 | 12-09-30 |
Cynthia Butitta
BRD | Director/Board Member | 70 | 17-09-30 |
Fred Cohen
BRD | Director/Board Member | 67 | 17-05-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.43% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 14.04 | -0.78% | 198,391 |
24-04-26 | 14.15 | +2.39% | 135,619 |
24-04-25 | 13.82 | -2.74% | 185,411 |
24-04-24 | 14.21 | -2.20% | 97,025 |
24-04-23 | 14.53 | +1.11% | 216,766 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.40% | 479M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.65% | 22.18B | |
-16.67% | 21.2B | |
-8.58% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- URGN Stock